Page last updated: 2024-09-05

lapatinib and thiophenes

lapatinib has been researched along with thiophenes in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (thiophenes)	Trials (thiophenes)	Recent Studies (post-2010) (thiophenes)
1,919	305	1,442	17,012	1,961	8,038

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR	1
Blanco-Aparicio, C; Cunningham, D; Eustace, AJ; Hennessy, BT; Kennedy, SP; Martinez, S; Morris, PG; O'Neill, M; Pastor, J; Toomey, S	1

Other Studies

2 other study(ies) available for lapatinib and thiophenes

Article	Year
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science translational medicine, 2017, Aug-02, Volume: 9, Issue:401 Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2017
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene, 2020, Volume: 39, Issue:14 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Trastuzumab	2020

Article

Year

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Science translational medicine, 2017, Aug-02, Volume: 9, Issue:401

Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.

Oncogene, 2020, Volume: 39, Issue:14

Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Trastuzumab

2020